Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
LQDA Stock 12 Month Forecast
Average Price Target
$47.50
▲(38.93% Upside)
| Highest Price Target$67.00 | Average Price Target$47.50 | Lowest Price Target$31.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$35→$50
Buy
46.24%
Upside
Reiterated
11/04/25
Raymond James
$41→$47
Buy
37.47%
Upside
Reiterated
11/04/25
BTIG
$49
Buy
43.32%
Upside
Reiterated
11/03/25
Positive Outlook for Liquidia Technologies: Strong Financial Performance and Growth Prospects Justify Buy RatingWe remain most focused on the highly binary '327 trial outcome (we recently discussed the case with an IP trial attorney - our takeaways from the call can be found HERE) and expect that the discount in LQDA shares vs. earnings growth potential (along with today's intraday fade, despite the strong beat) is most attributable to this legal overhang. LQDA achieved non-GAAP profitability in 3Q25 and a 189% beat in Yutrepia revenue ($54.3M vs. $18.8M consensus). Yutrepia uptake (>1,500 patients on Tx and >2,000 unique prescriptions to date) likely exceeds our prior expectations of 950 payor-reimbursed pts on Tx by the end of October. Rate of conversion also improved to 85% vs. 75% in 2Q25. Mgmt. indicated that PAH accounts for the majority of Yutrepia's TRx, with steady growth in PH-ILD; we expect the latter over time to emerge as the larger market opportunity for Yutrepia.
Needham
$36→$52
Buy
52.09%
Upside
Reiterated
11/03/25
Bank of America Securities
$37→$39
Buy
14.07%
Upside
Reiterated
11/03/25
LifeSci Capital
$54→$67
Buy
95.96%
Upside
Reiterated
11/03/25
Jefferies
$43→$45
Buy
31.62%
Upside
Reiterated
11/03/25
Wells Fargo
$31
Buy
-9.33%
Downside
Reiterated
10/17/25
We are maintaining the current ratings, price targets, and estimates.
Oppenheimer
$6
Sell
-82.45%
Downside
Reiterated
07/29/25
Scotiabank
$37
Buy
8.22%
Upside
Reiterated
06/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$35→$50
Buy
46.24%
Upside
Reiterated
11/04/25
Raymond James
$41→$47
Buy
37.47%
Upside
Reiterated
11/04/25
BTIG
$49
Buy
43.32%
Upside
Reiterated
11/03/25
Positive Outlook for Liquidia Technologies: Strong Financial Performance and Growth Prospects Justify Buy RatingWe remain most focused on the highly binary '327 trial outcome (we recently discussed the case with an IP trial attorney - our takeaways from the call can be found HERE) and expect that the discount in LQDA shares vs. earnings growth potential (along with today's intraday fade, despite the strong beat) is most attributable to this legal overhang. LQDA achieved non-GAAP profitability in 3Q25 and a 189% beat in Yutrepia revenue ($54.3M vs. $18.8M consensus). Yutrepia uptake (>1,500 patients on Tx and >2,000 unique prescriptions to date) likely exceeds our prior expectations of 950 payor-reimbursed pts on Tx by the end of October. Rate of conversion also improved to 85% vs. 75% in 2Q25. Mgmt. indicated that PAH accounts for the majority of Yutrepia's TRx, with steady growth in PH-ILD; we expect the latter over time to emerge as the larger market opportunity for Yutrepia.
Needham
$36→$52
Buy
52.09%
Upside
Reiterated
11/03/25
Bank of America Securities
$37→$39
Buy
14.07%
Upside
Reiterated
11/03/25
LifeSci Capital
$54→$67
Buy
95.96%
Upside
Reiterated
11/03/25
Jefferies
$43→$45
Buy
31.62%
Upside
Reiterated
11/03/25
Wells Fargo
$31
Buy
-9.33%
Downside
Reiterated
10/17/25
We are maintaining the current ratings, price targets, and estimates.
Oppenheimer
$6
Sell
-82.45%
Downside
Reiterated
07/29/25
Scotiabank
$37
Buy
8.22%
Upside
Reiterated
06/11/25
Best Analysts Covering Liquidia Technologies
1 Month
xxx
Success Rate
10/15 ratings generated profit
Average Return
+3.80%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.80% per trade.
3 Months
xxx
Success Rate
10/15 ratings generated profit
Average Return
+19.05%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +19.05% per trade.
1 Year
Success Rate
15/15 ratings generated profit
Average Return
+90.03%
reiterated a buy rating 6 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +90.03% per trade.
2 Years
xxx
Success Rate
26/26 ratings generated profit
Average Return
+146.72%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +146.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
LQDA Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
21
7
13
15
14
Buy
5
5
5
1
1
Hold
10
6
9
11
12
Sell
0
0
0
0
0
Strong Sell
1
1
0
0
0
total
37
19
27
27
27
Each month's total comprises the sum of three months' worth of ratings.
LQDA Financial Forecast
LQDA Stock Forecast FAQ
What is LQDA’s average 12-month price target, according to analysts?
Based on analyst ratings, Liquidia Technologies Inc’s 12-month average price target is 47.50.
What is LQDA’s upside potential, based on the analysts’ average price target?
Liquidia Technologies Inc has 38.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is LQDA a Buy, Sell or Hold?
Liquidia Technologies Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Liquidia Technologies Inc’s price target?
The average price target for Liquidia Technologies Inc is 47.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $67.00 ,the lowest forecast is $31.00. The average price target represents 38.93% Increase from the current price of $34.19.
The highest analyst price target is $67.00 ,the lowest forecast is $31.00. The average price target represents 38.93% Increase from the current price of $34.19.
What do analysts say about Liquidia Technologies Inc?
Liquidia Technologies Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of LQDA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.